| Name | NADH-cytochrome b5 reductase 2 | ||
| UniProt ID | NB5R2_HUMAN | ||
| Gene Name | CYB5R2 | ||
| Gene ID | 51700 | ||
| Synonyms |
CYB5R2, B5R.2
|
||
| Sequence |
MNSRRREPITLQDPEAKYPLPLIEKEKISHNTRRFRFGLPSPDHVLGLPVGNYVQLLAKI
DNELVVRAYTPVSSDDDRGFVDLIIKIYFKNVHPQYPEGGKMTQYLENMKIGETIFFRGP RGRLFYHGPGNLGIRPDQTSEPKKTLADHLGMIAGGTGITPMLQLIRHITKDPSDRTRMS LIFANQTEEDILVRKELEEIARTHPDQFNLWYTLDRPPIGWKYSSGFVTADMIKEHLPPP AKSTLILVCGPPPLIQTAAHPNLEKLGYTQDMIFTY |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa51700 | ||
| Pfam | PF00175; PF00970; PF08021; PF08030 | ||
| Pair Name | Atractylenolide I, Erlotinib | |||
| Phytochemical | Atractylenolide I | |||
| Drug | Erlotinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Regulate Info | Down-regulation | NADH-cytochrome b5 reductase 2 | Expression | |
| Result | Targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer | |||
